特比澳(重组人血小板生成素打针液)(国外英文资料).docVIP

特比澳(重组人血小板生成素注射液)(国外英文资料) Tribiao (recombinant thrombocyte injection) 【 drug name 】 The name of the commodity: tbiao Generic name: recombinant platelet product injection The name Recombinant Human is bopoietin Injection 【 composition 】 Recombinant platelet products, human blood albumin, sodium chloride 【 indications 】 Thrombocytopenia, which is caused by the treatment of the chemotherapy of solid tumor, is suitable for patients with platelets below 50 x 109 / L and doctors think it is necessary to elevate platelet therapy. [usage] This article should be used by clinicians. Specific usage, dosage and course due to illness, the recommended dose and method is as follows: malignant solid tumor chemotherapy, is expected to doses may cause thrombocytopenia and cause hemorrhage and increasing small plate, can be ended for 6 ~ 24 hours after subcutaneous injection of this product, the dose of daily per kilogram of body weight 300 u, once per day, the continuous application of 14 days; When the platelet count is recovered to 100109 / L, or the absolute absolute value of platelet counts increases by 50109 / L, it should be discontinued. When chemotherapy with white blood cells reduce or severe anemia, this product can be respectively with recombinant human granulocyte colony stimulating factor (rhG CSF) or recombinant human erythropoietin (rhEPO) combination. [adverse reaction] Few adverse reactions, occasionally have fever, muscle ache, dizziness, etc., do not need to deal with, more can self-heal. The symptoms of individual patients are clearly symptomatic. No severe adverse reactions were seen in phase III clinical trials. In 311 case subjects with 18 cases (3.86%), a total of 12 cases in connection with mild adverse reactions of rhTPO medication, including 4 cases were fever, chill in 2 cases, 1 column body unwell, lack of power in 2 cases, knee pain in 2 cases, 2 cases of headache, dizziness, 3 cases, increase blood pressure in 2 cases, symptoms are mild, without specia